The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

ABSTRACT:

Background

Limited data exist on the real-world costs of applying whole-genome analysis (WGA) in a clinical setting. We estimated the costs of applying WGA to guide treatments for patients with advanced cancers and characterized how costs evolve over time.

Methods

The setting is the British Columbia Cancer Agency Personalized OncoGenomics (POG) program in British Columbia, Canada. Cost data were obtained for patients who enrolled in the program from 2012 to 2015. We estimated mean WGA costs using bootstrapping. We applied time series analysis and produced 10-year forecasts to determine when costs are expected to reach critical thresholds.

Results

The mean cost of WGA over the study period was CDN$34,886 per patient (95% CI: $34,051, $35,721). Over time, WGA costs decr

SUBMITTER: Weymann D 

PROVIDER: S-EPMC5441418 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature